What is the appropriate management for a patient with sinus rhythm 48–123 bpm, frequent premature atrial contractions (~1200), occasional premature ventricular contractions (~194), no tachyarrhythmias or significant pauses, and symptoms occurring during normal sinus rhythm?

Management of Frequent Premature Atrial Contractions with Symptoms During Normal Sinus Rhythm

For this patient with frequent PACs (1201), occasional PVCs (194), and symptoms during normal sinus rhythm, initiate oral beta-blockers, diltiazem, or verapamil as first-line therapy, and if symptoms persist despite medical management or the patient prefers definitive treatment, proceed directly to catheter ablation. 1

Initial Management Approach

The ACC/AHA/HRS guidelines clearly establish that oral beta-blockers, diltiazem, or verapamil are first-line therapy for ongoing management of symptomatic supraventricular arrhythmias without ventricular pre-excitation 1. This applies directly to your patient's frequent PACs causing symptoms.

Key Clinical Considerations:

• The symptom-rhythm correlation is critical here: Your patient has symptoms during normal sinus rhythm, which suggests the PACs themselves (not the sinus rhythm) are likely causing the symptoms through frequent interruptions of normal rhythm
• PAC burden of 1201 is substantial and falls into the "frequent" category that warrants intervention 2
• The PVC burden (194) is relatively low and unlikely to be clinically significant 3

Treatment Algorithm

Step 1: Medical Therapy (First-Line)

Start with one of these options:

• Beta-blockers (metoprolol, atenolol, or carvedilol)
• Diltiazem
• Verapamil

These medications suppress ectopic atrial activity and are guideline-recommended as Class I, Level B evidence 1.

Step 2: Alternative Pharmacologic Options if First-Line Fails

If beta-blockers or calcium channel blockers are ineffective or contraindicated:

• Flecainide or propafenone are reasonable second-line agents in patients without structural heart disease or ischemic heart disease (Class IIa recommendation) 1
• Ensure you exclude structural heart disease with echocardiography before using these agents

Step 3: Catheter Ablation (Definitive Treatment)

Electrophysiological study with ablation is a Class I recommendation for diagnosis and treatment of symptomatic SVT 1. This should be strongly considered because:

• Recent data shows catheter ablation is highly effective for frequent, symptomatic PACs with success rates of 91.4% (32/35 patients) remaining free of recurrence after initial ablation 2
• PACs most commonly originate from pulmonary veins (20%), crista terminalis (17%), and para-Hisian areas (17%) 2
• Ablation prevents potential progression to atrial fibrillation, as frequent PACs are associated with increased AF risk 2
• The 2017 study demonstrated that symptomatic, drug-refractory PACs can be successfully eliminated with focal ablation or pulmonary vein isolation 2

Critical Pitfalls to Avoid

1. Do not dismiss symptoms during "normal sinus rhythm": The Holter report shows symptoms were associated with NSR, but this likely means symptoms occurred when the rhythm strip showed sinus rhythm between the PACs. The frequent PACs (1201) are almost certainly the culprit.

2. Rule out PAC-induced cardiomyopathy: With this PAC burden, obtain an echocardiogram to assess left ventricular function. A 2023 case report demonstrated that frequent PACs can cause reversible cardiomyopathy 4, and successful ablation normalized ventricular function.

3. Assess for bradycardia: Your Holter shows a minimum heart rate of 48 bpm. Blocked PACs can cause symptomatic bradycardia by resetting the sinoatrial node 5. If bradycardia is symptomatic, propafenone has been used successfully 5, though this is a nuanced situation requiring careful evaluation.

4. Do not use digoxin, amiodarone, or AV nodal blockers if pre-excitation is present: Ensure the baseline ECG shows no delta waves before prescribing calcium channel blockers or beta-blockers 6.

Practical Clinical Pathway

Immediate actions:

• Verify no pre-excitation on 12-lead ECG
• Obtain echocardiogram to exclude structural heart disease and assess LV function
• Educate patient on vagal maneuvers for acute symptom relief 1

Treatment sequence:

1. Start beta-blocker or calcium channel blocker
2. Reassess symptoms in 4-6 weeks
3. If symptoms persist or patient prefers definitive therapy, refer for EP study and ablation
4. If ablation is declined or contraindicated, trial flecainide/propafenone (after excluding structural heart disease)

The coupling intervals matter: Research shows PACs with shorter coupling intervals (<400 ms) are more likely to trigger atrial fibrillation 2. Your patient's PACs during NSR likely have longer coupling intervals, suggesting lower immediate AF risk, but the high burden still warrants treatment.